Tyra Biosciences Inc

The stock is in a Stage 3 distribution with declining EMAs and failed rally attempts, indicating a bearish medium-term environment. Short-term price action shows rejection at dynamic resistance after an oversold bounce, favoring sell-side execution on any rallies into the EMA zone. The long-term trend remains down with price below a falling 200DMA, anchoring a structural bearish bias.

• ↑SURF302 program enters pivotal trials with initial data due Sep 2026
• ↑$353.9 M cash reserves fund R&D through H2 2028
• ↓Earnings yield at –1.7% highlights poor revenue-to-profit conversion